Research
report -An
analysis
and
evaluation
of
the
business
and
financial
performance
of
an
organisation over a three year period
1.
Reasons for choosing topic and organisation:
In
recent
years,
the
medicine
market
demand
continued
to
rise
in
the
end
of
the
scale.
The
pharmaceutical
industry
has
sustained
high
growth
in
these
years.National
hospital
terminal
purchase market size reached about 246 billion in every country. The scale of the drug market will
be
up
to
769.6
billion,
accounted
for
ratio
which
can
reach
more
than
60%.
The
income
of
traditional medicine is up to 384.8 billion, accounting for 30% in a way. The income ofbiological
medicine
is
86.9
billion,
accounted
for
more
than
7%.
At
the
same
time,
in
the
recent
years
governments in health investment has increased year by year, 19980 billion from 2010 to 2014
36999.85 billion. Health expenditure in the GDP proportion is steadily improving.
The
broad
market
capacity
is
the
basic
of
economy
development .Sustainable
development
of
pharmaceutical
industry
in various
countries
in
health
industry
market
capacity
of nearly 4500
billion
in
aspect
of
income
in
2014,
which
the
medical
service
market
capacity
is
2.14
billion,
accounted for nearly 50%. The income of drug market capacity is about 40%. The income of the
equipment
accounted
for
3%.
Under
the
influence
of
drug
price
reform,
medicine
income
accounted
for
than
will
gradually
decline,
medical
services
accounted
for
the
ratio
will
be
improved accordingly.
Pharmaceutical
industry
is
growing
faster
than
GDP
.
Since
2011,
the
pharmaceutical
industry
added value growth sustained higher than the overall level of national industrial (3% - 5%), far
higher
than
the
other
industry
and
pharmaceutical
industry
in
national
industry
accounted
for
ratio continues to increase, in 2007 which accounted for 1.5% to 2014 (2.2%).
But in recent years, the accident of the pharmaceutical industry is frequent, the policy landing is
intensive,
the
future
situation
of
the
industry
is
uncertain.
So
we
should
how
to
develop
it?
Pharmaceutical enterprises how to face the new policy
and make new adjustment? Facing the
new
a
series
of
difficult
problems,
the
pharmaceutical
industry
should
do
what
to
how
to
innovate,
to
lower
the
cost.
At
the
same
time,the
pharmaceutical
industryshould
do
what
to
supply
drug
demand
of
high
quality
to
satisfy
the
people,
how
to
deal
with
the
contradiction
between the doctor and the patient. These problems have attracted much attention.
Hikma
group
was founded
in
1978
by
SamihDarwazah,
a
multinational pharmaceutical
company. The group early in the business strategy is mainly for the Middle East market
production affixed with the trademark not registered drug. In the 1980s early, Hikma group
on
the
basis
of
the
original
product,
an
increase
of
multinational
pharmaceutical
companies
in
the
production
of
registered
drug
to
supplement
its
sales
and
sending
structure.
Since
then
Hikma
group
has
achieved
rapid
development,
in
the
world
established branch. At present, the group in the Middle East and North Africa, Europe and
the United States has six branch, in Algeria and a company is under construction.
HikmaHikma
pharmaceuticals
company
(Amman,
Jordan)
is
the
first
group
operating
company
for
the
Arab
world
was
the
first
U.
S.
Food
and
Drug
Administration
(FDA)
license in the United States sales of its pharmaceutical company. The company also won
the UK medicines
and Healthcare Products Management Agency (MHRA) license, you
can in the UK drug sales. The company's main factory has a variety of functions, not only
can save raw materials, but also can carry out research and development, but also the
production
of
drugs
and
quality
detection.
In
addition
to
the
main
outside
the
factory,